Lindsay Anne Magura Rein

Conference Neuro-Oncology · November 11, 2025 AbstractImmunotherapies remain largely ineffective against intracranial malignancies such as glioblastoma (GBM), in part due to profound systemic and local immune dysfunction. Hallmarks of systemic immune ... Full text Cite

The effect of bezuclastinib on the pathobiology of mastocytosis: Changes in BM mast cells, tryptase, and KIT p.D816V variant allele frequency from the pivotal summit trial

Conference Blood · November 3, 2025 AbstractBackground: Systemic mastocytosis (SM) includes a spectrum of hematologic malignancies characterized by a variable degree of neopla ... Full text Cite

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Conference Blood · November 3, 2025 AbstractBackground: PIM1 is overexpressed in hematologic malignancies, including myelofibrosis (MF), contributing to disease progression by ... Full text Cite

Incidence, prevalence, and clinical outcomes of myelofibrosis with and without cytopenia in the United States

Conference Blood · November 3, 2025 AbstractIntroduction: Cytopenia in patients with myelofibrosis (MF) is characterized by presence of anemia and/or thrombocytopenia, and is ... Full text Cite

Cytopenia Is Associated With Real-World Disease Progression and Diminished Survival in Patients With Myelofibrosis: Analysis of a US National Administrative Claims Database

Conference CLINICAL LYMPHOMA MYELOMA & LEUKEMIA · September 2025 Link to item Cite

Prevalence of cytopenic myelofibrosis in the United States.

Conference Journal of Clinical Oncology · June 2025 e18575Background: Among patient (pts) with myelofibrosis (MF), cytopenias (anemia or thrombocytopenia) are a marker of advanc ... Full text Cite

Efficacy and Safety Results of Adult Patients with NonAdvanced Systemic Mastocytosis Receiving Bezuclastinib 100 mg in the Ongoing Summit Trial: A Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial of Bezuclastinib

Conference JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY · February 2025 Link to item Cite

Management and Outcomes of Patients Diagnosed with Chronic Myeloid Leukemia in Blast Phase: A Multicenter Analysis By the H Jean Khoury Cure CML Consortium

Conference Blood · November 5, 2024 Introduction:Despite advent of multiple tyrosine kinase inhibitors (TKIs) and newer treatment methods for both AML and ALL, the outcomes of patients (p ... Full text Cite

U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML)

Conference Blood · November 5, 2024 Introduction: The incidence of CML in the United States (U.S) is 1-2 cases per 100,000 persons per year and the prevalence has risen, in part due to the effectiveness of BCR-ABL1 tyrosine ... Full text Cite

HJKC3-0006: Outcome of Patients with CML Treated on Second Line or Later Therapy in Routine Clinical Practice

Conference Blood · November 2, 2023 Background: First-line therapies for chronic-phase (CP) CML include the tyrosine kinase inhibitors(TKIs) dasatinib, nilotinib, bosutinib or imatinib, while ponatinib and asciminib are indicated only in later lines. Ther ... Full text Cite

HJKC3-007: Outcomes of Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Asciminib and Other Tyrosine Kinase Inhibitors in Routine Clinical Practice

Conference Blood · November 2, 2023 Background and significance: There are typically high response rates to first line TKI therapies in chronic phase chronic myeloid leukemia (CP-CML). However, responses in later lines (second line and beyond) are diminis ... Full text Cite

Preliminary gastrointestinal safety and tolerability of fedratinib from the phase IIIb FREEDOM trial in patients with intermediateor high-risk myelofibrosis previously treated with ruxolitinib

Conference BRITISH JOURNAL OF HAEMATOLOGY · April 2021 Link to item Cite

MPN-183: Preliminary Gastrointestinal Safety and Tolerability of Fedratinib from the Phase IIIb FREEDOM Trial in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib

Conference Clinical Lymphoma Myeloma and Leukemia · September 2020 Full text Cite

Lindsay Anne Magura Rein

Scholarly Works - Conferences

Improvement of Symptom Burden in Summit: Bezuclastinib in Adults with Non-Advanced Systemic Mastocytosis

Results From the Phase 2 Summit Trial of Bezuclastinib in Adults with Non-Advanced Systemic Mastocytosis: Patient Experience of Living with NonAdvSM

Results from the Summit pivotal trial: Symptom improvement correlates with reductions in objective measures of disease in adults with non-advanced systemic mastocytosis

Evaluation of Bone Formation Marker Changes in Summit, a Trial Assessing Bezuclastinib in Adults with Non-Advanced Systemic Mastocytosis : An Exploratory Analysis

IMMU-81. Glioblastoma and other intracranial pathologies elicit systemic sympathetic hyperactivity that limits immunotherapeutic responses